27 Oct 2008

BioPartnering Europe (BPE) Continues to Stand Out as Europe's Premier Biotech Partnering Conference

Technology Vision Group LLC (TVG) is delighted to announce that as BPE enters its 16th year it continues to stand out as Europe's premier biotech partnering conference. Over 1086 delegates from the international biotech and pharma industry participated in BPE, which took place on October 12-14th at the QEII Conference Centre in London.

This year there were well over 5,555 meetings scheduled via the biopartnering.com software, with numerous other meetings arranged ad hoc, at what proved to be a lively and engaging event. The meetings were facilitated by biopartnering.com, TVG's powerful internet platform, developed to enhance conference participation before, during and after BPE, allowing attendees to make the most of their time at the conference and capitalise on all the opportunities afforded by BPE.

Dr. Alistair Irvine, Director of Business Developmentat Kuros Biosurgery AG, Switzerland, who attended the conference said:

"BioPartnering Europe was a great platform from which tofurther develop Kuros'partneringactivities. We were able to arrange a multitude of meetings with a great range of companies from all over the world. I would recommend attending the conference to those companies who want to broadentheir organisation's partnering and networking opportunities."
As in previous years the Leadership Sessions were a significant attraction for delegates and discussed some of the most pressing challenges for the life science industry today. The Session entitled, "Partner, Sell, or Go It Alone - Deal Strategies for Building a Successful Biotech Company in a Tough World," saw animated discussions between deal gurus and finance experts as they analysed the current state of the markets and deal making and the strategies that have led to success. In another Leadership Session, "Deal or No Deal" a highly experienced panel reviewed and discussed market expectations for deal terms in the life sciences sector and market reaction to recent deals done.

One of the panellists, Crispin Simon CEO of Biocompatibles International plc commented:
"It was a great opportunity to be able to speak at the conference and share Biocompatibles' deal experiences. We really enjoyed the BioPartnering conference and made some really worthwhile progress in discussions with potential partners for our RNAi-delivering polymer systems."

Delegates enjoyed three days of unique networking opportunities, designed to help life science companies meet with potential new partners and investors, including an evening reception at London's Science Museum.


The BioForecaster -- Fall 2008 is consistently one of the highlights of the London conference. This year, the panel of experts included Stuart Henderson of Deloitte, Dr. Sam Fazeli of Piper Jaffray, John Hodgson of Critical I, Antoine Papiernik of Sofinnova Partners and Dr. Andrew Richards.

The session looked at significant trends in the biotech industry against a background of ever increasing financial challenges. The panellists covered topics such as company strategy, the future of venture capital funding, investment trends, and drew comparisons between the early stage companies and public companies. In general, the panellists were in agreement that the next year will be difficult for the biotech industry, however in spite of this, the future of sector was positive and that by BPE 2009 the worst of the credit crunch would be behind us.
Finally, Sponsors workshops were very successful and provided interactive and practical insights on a number of issues, including licensing and collaboration agreement disputes and strategies for licensing your biotech products to pharma.

The sister Conference of BPE, the 7th Annual BioPartnering North America will take place on February 8 - 10, 2009 in Vancouver, British Columbia, Canada. The 17th Annual BioPartnering Europe will be held on October 11-13, 2009, in London, UK.

For all details about BioPartnering Europe and BioPartnering North America please go to http://www.techvision.com.

About Technology Vision Group

Technology Vision Group LLC (TVG) is one of the leading business development organizations serving the international life sciences industry. Since 1992, TVG has been developing innovative methods to help life science and associated technology companies attract partners and investors, acquire new products and technologies, and achieve a variety of other strategic business development goals.

Confirmed Presenting Companies:
4- Antibody AG, Ablynx, ACE BioSciences A/S, Aerie Pharmaceuticals, Inc, Affitech AS/ Affitech USA, Inc., Agile Therapeutics, AlgoNomics NV, Allergy Therapeutics plc, Alligator Bioscience AB, Allozyne, Ambit Biosciences, AM-Pharma B.V., Apthera, Inc., Aquinox Pharmaceuticals Inc., Arana Therapeutics Limited, Archimedes Pharma Ltd, Ardea Biosciences, Asphelia Pharmaceuticals, Avecia Limited, Balter Inc. (& PhotoSense AS), BaroFold, Inc, Baxter Asia Pacific, Bio Nano Centre, Biocompatibles International plc, Biocontrol Ltd, BioFocus DPI Limited, Biolex Therapeutics, Inc., BioSeek, Inc., BiPar Sciences, Inc, BN ImmunoTherapeutics, BTG, Calabar AB, Celleron Therapeutics, Cellzome Inc., Cequent Pharmaceuticals, Ceregene Inc., Cerenis Therapeutics, Circassia, Clinical Data, CNSBio Pty Ltd, CoLucid Pharmaceuticals, Inc., CoMentis, Inc., Concert Pharmaceuticals, Inc., Critical Pharmaceuticals Ltd, Cumbre Pharmaceuticals Inc., Curis, Inc., Cyclacel Limited, Cytokinetics, Inc., DBV-Technologies, Debiopharm SA, deCODE chemistry & biostructures, Delcath Systems, Inc., Delphi Genetics, Direvo Biotech AG, e2v biosensors, EcoBiotics Ltd, Egalet a/s, Emergent BioSolutions, Endoceutics, EntreMed, Inc., EquinOx Pharmaceuticals Corporation, Essentialis, Inc., Eurand S.p.A., Evotec, Flamel Technologies SA, f-star Biotechnology, Ganymed Pharmaceuticals AG, Genera Biosystems Limited, Glytech, Haemostatix Ltd, Halozyme Therapeutics, Health Protection Agency, Heptares Therapeutics Ltd, Hyposafe A/S, ImmunoVaccine Technologies Inc. (IVT), Indevus Pharmaceuticals, Inc., Innate Pharma, InNexus Biotechnology Inc., Intas Biopharmaceuticals Ltd, Interleukin Genetics, Inc., Intermune, Inc., Ipsat Therapies Oy, Isconova, Jazz Pharmaceuticals, Inc., KAI Pharmaceuticals Inc., Lamellar Biomedical Limited, Lectus Therapeutics Ltd, Lentigen Corporation, LifeCycle Pharma, Inc., MBC Pharma, Inc, Medelis, Inc., MedPharm Ltd, Micromet, Inc., Moberg Derma AB, Modern Biosciences, Molecular Profiles Ltd, MolMed SpA, MorphoSys AG, Napo Pharmaceuticals, Inc., Nektar Therapeutics, NeoGenix Oncology, Inc., Neurobiological Technologies Inc., Neurocrine Biosciences, Inc., Neurotech Pharmaceuticals, NextPharma, Norgine, Novacta Therapeutics, Novosom AG, Novozymes A/S, NsGene A/S, Numerate, Inc., Office of Biomedical Advanced Research and Development Authority (BARDA), Olink Bioscience, Oncolytics Biotech Inc., OptiNose, Panacos Pharmaceuticals, Inc., PharmaNova, PlexPress, PolyMedix Inc., Polytherics, Presidio Pharmaceuticals, Inc., Probiodrug AG, ProCell Therapeutics, Inc./Chonnam National University, Pronota nv, Propanc Pty Ltd, Prosonix Ltd, Protalix Biotherapeutics, Q Chip Ltd, Receptor BioLogix, Revotar Biopharmaceuticals AG, Sciclone Pharmaceuticals, Selvita, SemBioSys Genetics Inc., Sequoia Sciences, Inc., Serodus AS, Serometrix LLC, Shire Pharmaceuticals, Inc., Sidec AB, Silence Therapeutics AG /plc, Simcere Pharmaceutical Incorporation, Spectrum Pharmaceuticals, Inc., Summit plc, SuperGen, Inc., Suven Life Sciences Limited, Symphogen A/S, Synageva BioPharma, Synosia Therapeutics Inc, Syntaxin Ltd, Tetraphase Pharmaceuticals,The University of Nottingham, Therosteon, Theryte Ltd, TopoTarget A/S, Transcept Pharmaceuticals, Transdel Pharmaceuticals, Inc., Tranzyme Pharma, TriStar Technology Group, LLC., Trophos, UCB Group, Vakzine Projekt Management GmbH, ValiBIO SA, Verva Pharmaceuticals Ltd., Vivostat A/S, VLST, Vyteris, Inc., Xenome Ltd., XOMA LTD, YM BioSciences Inc.


AstraZeneca, Deloitte, Takeda Pharmaceuticals, Taylor Wessing, Cooley, Ferghana Partners, Goodwin Procter, Abbott, Amgen, Bristol-Myers Squibb, Glaxo-Smith Kline, International Business Wales, Johnson & Johnson, Merck, Novartis, Pfizer, Procter & Gamble Pharmaceuticals, Roche, UKTI, Farris, Vaughan, Wills and Murphy, ImmuPharma, and Genzyme

Conference Supporters

BioCentury, BioPharm International, BioSquare, Biotech 360, BioWorld Today, Business Wire, Citigate Dewe Rogerson, European Biotechnology News, Nature Publishing Group, The Scientist

GBP Supporters

apbio, Bay Bio, BIA, BIOCOM, BioEvents, Bionow, ERBI, European Federation of Biotechnology, Federchimica ASSOCBIOTEC, Fundacao Biominas, LifeSciences, Oxfordshire Bioscience Network, British Columbia, UBI France, WBBA

SOURCE: Technology Vision Group LLC Attendees:
Technology Vision Group, LLC
Rebecca Angelos (Director), +1 831 464 4230 ext. 153
Media Registration:
Citigate Dewe Rogerson
Helena Galilee / Amber Bielecka, +44 (0)207 282 1052

No comments:

Biotech Career | Pharmacy Career | Biotech Jobs | Chemistry Career | Jobs India